查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1625245

2030 年肾上腺素自动注射器市场预测：按产品、剂量、年龄层、品牌、应用、最终用户和地区进行的全球分析

Epinephrine Auto-Injectors Market Forecasts to 2030 - Global Analysis By Product (Single-dose Auto-Injectors and Multi-dose Auto-Injectors), Dosage, Age Group, Brand, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2024 年全球肾上腺素自动注射器市场规模为 23.3 亿美元，预计预测期内复合年增长率为 6.3%，到 2030 年将达到 33.7 亿美元。

肾上腺素自动注射器是医疗设备，肾上腺素是一种用于治疗严重过敏反应（过敏反应）的救命药物。这些紧凑的便携式设备含有预先测量的肾上腺素，并具有弹簧加载机构，可快速注射到大腿肌肉中。它透过收缩血管和放鬆气道肌肉来快速缓解症状，逆转肿胀、低血压和呼吸困难等症状。它通常被患有严重过敏的人使用，对于在危及生命的过敏紧急情况下即时做出反应至关重要。

根据世界卫生组织(WHO)的报告，到2021年，全球每年註射次数将超过160亿次，注射次数的增加正在推动自动注射器市场的发展。

过敏反应增加

严重过敏反应的病例数正在增加，因此及时采取替代治疗的需求变得越来越重要。肾上腺素自动注射器提供了一种在紧急情况下施用救生药物的快速便捷的方法。人们对过敏反应及其风险的认识不断提高，导致对这些设备的需求增加。自动注射器技术的进步提供了一个易于使用的设计，进一步推动了市场的发展。随着高风险族群的增加，肾上腺素自动注射器正成为管理过敏反应的重要工具，确保市场的持续成长。

产品召回和缺陷

产品召回和缺陷会带来严重的健康风险，例如自动注射器无法在紧急情况下准确注射剂量，导致使用者不愿意依赖自动注射器。召回会扰乱供应链，导致短缺，并使患者无法获得关键的医疗设备。此外，召回往往会导致监管审查加强，从而减缓新产品核准和市场扩张。召回和相关诉讼的财务负担也会影响製造商，限制他们投资创新的能力。

扩大适应症

随着食物过敏和昆虫叮咬等需要即时使用肾上腺素治疗的新疾病的出现，对自动注射器的需求不断增加。此外，医疗机构越来越认识到携带自动注射器以供紧急使用的重要性，进一步增加了其采用率。随着人们的广泛使用，市场规模不断扩大。配方和设备设计的进步也有助于提高患者的依从性和易用性。最终，扩大适应症将提高认知度和进入率，推动市场渗透和销售成长。

法律和道德问题

自动注射器的高成本通常是由于专利保护，这引发了有关可及性的道德问题，特别是对于低收入患者而言。围绕定价和垄断行为的监管障碍和诉讼为製造商创造了充满挑战的法律环境。学名药的缺乏、可负担性和市场竞争有限也引起了伦理问题。与设备故障和滥用相关的责任问题进一步抑制了创新和投资。总的来说，这些因素阻碍了救生自动注射器的市场成长和广泛采用。

COVID-19 的影响

COVID-19 大流行对肾上腺素自动注射器市场产生了重大影响。供应链中断、医疗机构患者就诊人数减少以及选择性治疗的延迟最初阻碍了市场成长。然而，人们对呼吸健康和自我护理的兴趣日益浓厚，导致对家庭治疗解决方案的需求增加，从而使市场受益。远端医疗和线上药局已成为停工期间的主要分销管道。製造商的应对措施是增加产量并确保准入。随着医疗保健的改善和供应链在疫情后的正常化，市场表现出韧性，逐渐復苏。

单剂量自动注射器细分市场预计将成为预测期内最大的细分市场

透过为面临严重过敏反应的人们提供便利和易用性，单剂量自动注射器市场预计将出现良好的成长。这些设备允许快速自我管理，并能够在紧急情况下及时管理肾上腺素。它们也被设计为便携的，适合在旅途中使用，从而提高了采用率。此外，监管部门的核准和设计创新正在提高单剂量自动注射器的可用性和有效性。因此，该细分市场继续为整体市场成长做出重大贡献。

预计医院业在预测期内复合年增长率最高。

由于可以即时获得针对过敏性紧急情况的救生治疗，预计医院部门在预测期内将出现最高的复合年增长率。医院通常是严重过敏反应患者的主要治疗地点，及时给予肾上腺素至关重要。随着全球过敏反应的增加，医院正在储备更多的自动注射器以满足紧急需求。此外，医疗保健专业人员对肾上腺素自动注射器使用的认识和培训正在推动医院的采用。

比最大的地区

由于人们对过敏反应及其管理的认识不断提高，食物过敏和其他严重过敏反应的盛行率不断增加，预计亚太地区将在预测期内占据最大的市场占有率。由于政府努力改善医疗保健和促进过敏管理，中国、印度和日本等国家的需求不断增长。自动注射器设计的技术进步，包括紧凑且易于使用的设备，也正在推动采用。此外，製药公司增加的投资和当地製造的合作伙伴关係正在提高整个全部区域的可用性和可负担性。

复合年增长率最高的地区：

由于过敏反应和过敏的盛行率不断增加，预计北美在预测期内将出现最高的复合年增长率。人们对过敏反应紧急治疗的认识不断提高以及对及时医疗干预的需求正在推动需求。美国因其高渗透率、医疗保健基础设施以及 EpiPen 和 Auvi-Q 等各种品牌的可用性而占据市场主导地位。随着保险覆盖范围的扩大，监理支持进一步提振市场。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场公司的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争标基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球肾上腺素自动注射器市场：按产品

  • 单剂量自动注射器
  • 多剂量自动注射器

第六章全球肾上腺素自动注射器市场：按剂量

  • 0.15mg
  • 0.3mg
  • 其他剂量

第七章全球肾上腺素自动注射器市场：依年龄组

  • 0-4岁
  • 5-14岁
  • 15-24岁
  • 25-49岁
  • 50-64岁
  • 65岁以上
  • 其他年龄段

第八章全球肾上腺素自动注射器市场：按品牌

  • EpiPen（迈兰/比阿特丽斯）
  • Auvi-Q（卡雷奥）
  • Adrenaclick（Enfaster 製药公司）
  • 非专利版本
  • 其他品牌

第九章全球肾上腺素自动注射器市场：依应用分类

  • 过敏反应
  • 食物过敏
  • 药物过敏
  • 其他用途

第10章全球肾上腺素自动注射器市场：依最终用户分类

  • 医院
  • 诊所
  • 家庭护理设置
  • 其他最终用户

第十一章全球肾上腺素自动注射器市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十二章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第十三章 公司概况

  • Viatris Inc.
  • Amneal Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Kaleo, Inc.
  • Pfizer, Inc.
  • Sanofi SA
  • Adamis Pharmaceuticals Corporation
  • Novartis International AG
  • Bausch Health Companies Inc.
  • ALK-Abello A/S
  • Hikma Pharmaceuticals PLC
  • Antares Pharma, Inc.
  • Meridian Medical Technologies, Inc.
  • Becton, Dickinson and Company
  • Ypsomed Holding AG
Product Code: SMRC28200

According to Stratistics MRC, the Global Epinephrine Auto-Injectors Market is accounted for $2.33 billion in 2024 and is expected to reach $3.37 billion by 2030 growing at a CAGR of 6.3% during the forecast period. Epinephrine auto-injectors are medical devices designed for emergency self-administration of epinephrine, a life-saving medication used to treat severe allergic reactions (anaphylaxis). These compact, portable devices contain a pre-measured dose of epinephrine and feature a spring-loaded mechanism for rapid injection into the thigh muscle. They provide quick relief by constricting blood vessels, relaxing airway muscles, and reversing symptoms like swelling, low blood pressure, and breathing difficulties. Commonly used by individuals with severe allergies, they are essential for immediate response during life-threatening allergic emergencies.

According to World Health Organization reports, over 16 billion injections were administered annually worldwide in 2021, stimulated by the increasing number of injections administered boosting the auto injector market.

Market Dynamics:

Driver:

Rising prevalence of anaphylaxis

The number of cases of severe allergic responses rises; the necessity for quick treatment alternatives becomes increasingly important. Epinephrine auto-injectors provide a fast and convenient way to administer life-saving medication in emergencies. Growing awareness about anaphylaxis and its risks has led to a heightened demand for these devices. The market is further fuelled by advancements in auto-injector technology, offering user-friendly designs. With an expanding at-risk population, epinephrine auto-injectors are becoming an essential tool for managing anaphylaxis, ensuring a sustained market growth.

Restraint:

Product recalls and malfunctions

Product recalls and malfunctions like failed delivery of auto-injectors to accurate doses during emergencies, it poses severe health risks, deterring users from relying on them. Recalls disrupt the supply chain and create shortages, leaving patients without access to critical medical devices. Additionally, recalls often lead to increased regulatory scrutiny, delaying new product approvals and market expansions. The financial burden of recalls and associated lawsuits also impacts manufacturers, limiting their ability to invest in innovation.

Opportunity:

Expansion of indications

The new medical conditions, such as food allergies and insect stings, are identified as requiring immediate epinephrine treatment, the demand for auto-injectors rises. Additionally, healthcare organizations are increasingly recognizing the importance of carrying auto-injectors for emergency use, further increasing their adoption. This broader usage across various demographics enhances market reach. Advancements in formulation and device design also contribute to greater patient compliance and ease of use. Ultimately, the expanded indications improve awareness and access, driving higher market penetration and sales.

Threat:

Legal and ethical concerns

High prices of auto-injectors, often attributed to patent protections, raise ethical questions about accessibility, especially for low-income patients. Regulatory hurdles and lawsuits over pricing and monopolistic practices create a challenging legal environment for manufacturers. Ethical concerns also arise from a lack of generic alternatives, limiting affordability and market competition. Liability issues related to device malfunctions or incorrect usage further deter innovation and investment. These factors collectively hinder the market's growth and broader adoption of life-saving auto-injectors.

Covid-19 Impact

The COVID-19 pandemic significantly impacted the epinephrine auto-injectors market. Disruptions in supply chains, reduced patient visits to healthcare facilities, and delayed elective treatments initially hindered market growth. However, the heightened focus on respiratory health and self-care led to increased demand for at-home treatment solutions, benefiting the market. Telemedicine and online pharmacies emerged as key distribution channels during lockdowns. Manufacturers adapted by ramping up production and ensuring accessibility. The market demonstrated resilience, with gradual recovery aligning with improved healthcare access and the normalization of supply chains post-pandemic.

The single-dose auto-injectors segment is expected to be the largest during the forecast period

The single-dose auto-injectors segment is estimated to have a lucrative growth, by offering convenience and ease of use for individuals facing severe allergic reactions. These devices provide quick, self-administered doses, ensuring timely epinephrine delivery in emergencies. They are designed for portability, making them suitable for on-the-go use, which increases their adoption rates. Furthermore, regulatory approvals and innovations in design have enhanced the accessibility and effectiveness of single-dose auto-injectors. As a result, this segment continues to contribute significantly to the growth of the overall market.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is anticipated to witness the highest CAGR growth during the forecast period, due to immediate access to life-saving treatment for anaphylactic emergencies. Hospitals often serve as the primary setting for patients experiencing severe allergic reactions, where rapid administration of epinephrine is critical. With increasing allergic reactions globally, hospitals are stocking more auto-injectors to meet emergency needs. Additionally, healthcare professionals' awareness and training in using epinephrine auto-injectors drive their adoption in hospitals.

Region with largest share:

Asia Pacific is expected to hold the largest market share during the forecast period due to rising awareness of anaphylaxis and its management, coupled with increasing prevalence of food allergies and other severe allergic reactions. Countries like China, India, and Japan are seeing growing demand due to improved healthcare access and government initiatives promoting allergy management. Technological advancements in auto-injector design, such as compact and user-friendly devices, are also boosting adoption. Additionally, rising investments by pharmaceutical companies and collaborations for local manufacturing are enhancing availability and affordability across the region.

Region with highest CAGR:

North America is expected to have the highest CAGR over the forecast period, owing to increasing prevalence of anaphylactic reactions and allergies. Rising awareness about emergency treatment for allergic reactions and the need for quick medical intervention are boosting demand. The U.S. dominates the market due to high adoption rates, healthcare infrastructure, and the availability of various brands like EpiPen and Auvi-Q. Regulatory support, along with expanding insurance coverage, is further propelling the market.

Key players in the market

Some of the key players profiled in the Epinephrine Auto-Injectors Market include Viatris Inc., Amneal Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Kaleo, Inc., Pfizer, Inc., Sanofi S.A., Adamis Pharmaceuticals Corporation, Novartis International AG, Bausch Health Companies Inc., ALK-Abello A/S, Hikma Pharmaceuticals PLC, Antares Pharma, Inc., Meridian Medical Technologies, Inc., Becton, Dickinson and Company and Ypsomed Holding AG.

Key Developments:

In October 2024, Viatris entered into an exclusive licensing agreement to acquire rights to sotagliflozin in all markets outside the U.S. and Europe. The partnership aims to enhance the commercial reach of sotagliflozin, which is relevant for patients with diabetes and heart failure.

In February 2024, Viatris announced a significant global research and development collaboration with Idorsia Ltd. The collaboration aims to leverage Viatris' infrastructure alongside Idorsia's drug development capabilities.

Products Covered:

  • Single-dose Auto-Injectors
  • Multi-dose Auto-Injectors

Dosages Covered:

  • 0.15 mg
  • 0.3 mg
  • Other Dosages

Age Groups Covered:

  • 0-4 Years
  • 5-14 Years
  • 15-24 Years
  • 25-49 Years
  • 50-64 Years
  • Above 65 Years
  • Other Age Groups

Brands Covered:

  • EpiPen (Mylan/Viatris)
  • Auvi-Q (Kaleo)
  • Adrenaclick (Amphastar Pharmaceuticals)
  • Generic Versions
  • Other Brands

Applications Covered:

  • Anaphylaxis
  • Food Allergies
  • Drug Allergies
  • Other Applications

End Users Covered:

  • Hospitals
  • Clinics
  • Homecare Settings
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Epinephrine Auto-Injectors Market, By Product

  • 5.1 Introduction
  • 5.2 Single-dose Auto-Injectors
  • 5.3 Multi-dose Auto-Injectors

6 Global Epinephrine Auto-Injectors Market, By Dosage

  • 6.1 Introduction
  • 6.2 0.15 mg
  • 6.3 0.3 mg
  • 6.4 Other Dosages

7 Global Epinephrine Auto-Injectors Market, By Age Group

  • 7.1 Introduction
  • 7.2 0-4 Years
  • 7.3 5-14 Years
  • 7.4 15-24 Years
  • 7.5 25-49 Years
  • 7.6 50-64 Years
  • 7.7 Above 65 Years
  • 7.8 Other Age Groups

8 Global Epinephrine Auto-Injectors Market, By Brand

  • 8.1 Introduction
  • 8.2 EpiPen (Mylan/Viatris)
  • 8.3 Auvi-Q (Kaleo)
  • 8.4 Adrenaclick (Amphastar Pharmaceuticals)
  • 8.5 Generic Versions
  • 8.6 Other Brands

9 Global Epinephrine Auto-Injectors Market, By Application

  • 9.1 Introduction
  • 9.2 Anaphylaxis
  • 9.3 Food Allergies
  • 9.4 Drug Allergies
  • 9.5 Other Applications

10 Global Epinephrine Auto-Injectors Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Clinics
  • 10.4 Homecare Settings
  • 10.5 Other End Users

11 Global Epinephrine Auto-Injectors Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Viatris Inc.
  • 13.2 Amneal Pharmaceuticals, Inc.
  • 13.3 Teva Pharmaceutical Industries Ltd.
  • 13.4 Kaleo, Inc.
  • 13.5 Pfizer, Inc.
  • 13.6 Sanofi S.A.
  • 13.7 Adamis Pharmaceuticals Corporation
  • 13.8 Novartis International AG
  • 13.9 Bausch Health Companies Inc.
  • 13.10 ALK-Abello A/S
  • 13.11 Hikma Pharmaceuticals PLC
  • 13.12 Antares Pharma, Inc.
  • 13.13 Meridian Medical Technologies, Inc.
  • 13.14 Becton, Dickinson and Company
  • 13.15 Ypsomed Holding AG

List of Tables

  • Table 1 Global Epinephrine Auto-Injectors Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Epinephrine Auto-Injectors Market Outlook, By Product (2022-2030) ($MN)
  • Table 3 Global Epinephrine Auto-Injectors Market Outlook, By Single-dose Auto-Injectors (2022-2030) ($MN)
  • Table 4 Global Epinephrine Auto-Injectors Market Outlook, By Multi-dose Auto-Injectors (2022-2030) ($MN)
  • Table 5 Global Epinephrine Auto-Injectors Market Outlook, By Dosage (2022-2030) ($MN)
  • Table 6 Global Epinephrine Auto-Injectors Market Outlook, By 0.15 mg (2022-2030) ($MN)
  • Table 7 Global Epinephrine Auto-Injectors Market Outlook, By 0.3 mg (2022-2030) ($MN)
  • Table 8 Global Epinephrine Auto-Injectors Market Outlook, By Other Dosages (2022-2030) ($MN)
  • Table 9 Global Epinephrine Auto-Injectors Market Outlook, By Age Group (2022-2030) ($MN)
  • Table 10 Global Epinephrine Auto-Injectors Market Outlook, By 0-4 Years (2022-2030) ($MN)
  • Table 11 Global Epinephrine Auto-Injectors Market Outlook, By 5-14 Years (2022-2030) ($MN)
  • Table 12 Global Epinephrine Auto-Injectors Market Outlook, By 15-24 Years (2022-2030) ($MN)
  • Table 13 Global Epinephrine Auto-Injectors Market Outlook, By 25-49 Years (2022-2030) ($MN)
  • Table 14 Global Epinephrine Auto-Injectors Market Outlook, By 50-64 Years (2022-2030) ($MN)
  • Table 15 Global Epinephrine Auto-Injectors Market Outlook, By Above 65 Years (2022-2030) ($MN)
  • Table 16 Global Epinephrine Auto-Injectors Market Outlook, By Other Age Groups (2022-2030) ($MN)
  • Table 17 Global Epinephrine Auto-Injectors Market Outlook, By Brand (2022-2030) ($MN)
  • Table 18 Global Epinephrine Auto-Injectors Market Outlook, By EpiPen (Mylan/Viatris) (2022-2030) ($MN)
  • Table 19 Global Epinephrine Auto-Injectors Market Outlook, By Auvi-Q (Kaleo) (2022-2030) ($MN)
  • Table 20 Global Epinephrine Auto-Injectors Market Outlook, By Adrenaclick (Amphastar Pharmaceuticals) (2022-2030) ($MN)
  • Table 21 Global Epinephrine Auto-Injectors Market Outlook, By Generic Versions (2022-2030) ($MN)
  • Table 22 Global Epinephrine Auto-Injectors Market Outlook, By Other Brands (2022-2030) ($MN)
  • Table 23 Global Epinephrine Auto-Injectors Market Outlook, By Application (2022-2030) ($MN)
  • Table 24 Global Epinephrine Auto-Injectors Market Outlook, By Anaphylaxis (2022-2030) ($MN)
  • Table 25 Global Epinephrine Auto-Injectors Market Outlook, By Food Allergies (2022-2030) ($MN)
  • Table 26 Global Epinephrine Auto-Injectors Market Outlook, By Drug Allergies (2022-2030) ($MN)
  • Table 27 Global Epinephrine Auto-Injectors Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 28 Global Epinephrine Auto-Injectors Market Outlook, By End User (2022-2030) ($MN)
  • Table 29 Global Epinephrine Auto-Injectors Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 30 Global Epinephrine Auto-Injectors Market Outlook, By Clinics (2022-2030) ($MN)
  • Table 31 Global Epinephrine Auto-Injectors Market Outlook, By Homecare Settings (2022-2030) ($MN)
  • Table 32 Global Epinephrine Auto-Injectors Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.